Inicio
Entrar
Ayuda
Buscar en este sitio:
Ensayos Registrados
Por tipo de intervención
Por estado de reclutamiento
Por promotor
Por fecha de registro
Búsqueda avanzada de ensayos
Proceso de Registro
Para registrar un ensayo
Formulario del Promotor
Formulario de ensayos del RPCEC
Para actualizar un ensayo registrado
Para reportar los resultados de un ensayo registrado
Inicio
|
Biomodulina T in pediatric septic shock. Exploratory study
View current
Revisiones
List all revisions
Ver
Compare to current
3 Agosto 2020 - 11:11am
por Gladys
5 Octubre 2020 - 11:45am
por lazara
Cambios a
Postal address of Ethic Committee
-
July 26th
Avenue
and 1st. Cast Escambray, Santa Clara. Villa Clara, ZC: 50200
. Cuba
+
July 26th
Av.
and 1st. Cast Escambray, Santa Clara. Villa Clara,
Cuba.
ZC: 50200
Cambios a
Record Verification Date
-
2020/
08
/
03
+
2020/
10
/
05
Cambios a
Next update date
-
2021/
08
/
03
+
2021/
10
/
05
Revisión de 5 Octubre 2020 - 11:45am
Biomodulina T in pediatric septic shock. Exploratory study
General information
Section to complete general information about the trial: scientific and public title, protocol identifiers, sponsors and Source(s) of Monetary or Material Support.
Scientific title:
Evaluation of the effect and safety of Biomodulina T in combination with conventional therapy in the treatment of pediatric septic shock. Exploratory Study.
Secondary indentifying numbers:
GEC2020BMT026
Issuing authority of the secondary identifying numbers:
Centro Nacional de Biopreparados (BioCen)
Primary sponsor:
Centro Nacional de Biopreparados (BioCen)
Secondary sponsor:
Not applicable
Source(s) of monetary or material support:
Centro Nacional de Biopreparados (BioCen) Ministry of Public Health (MINSAP)
Authorization for beginning
Section to complete information about the regulatory approval of clinical trial: regulatory agency name, approval date and reference number in the agency.
Regulatory instance to authorize the initiation of the study:
Center for State Control of Drugs, Medical Devices and Equipment (CECMED)
Reference number:
In process
Principal investigator
Section to complete information about Email address, telephone number and postal address of the Principal Investigator.
First name:
Yoandra
Last name:
Acevedo Rodriguez
Medical Specialty :
First degree specialist Integral General Medicine and First degree in Intensive Therapy and Emergency (pediatric profile).
Affiliation:
"Jose Luis Miranda" Pediatric Hospital.
Postal address:
July 26th Avenue and 1st. Reparto Escambray, Santa Clara
City:
Villa Clara
País:
Cuba
Zip Code:
50200
Telephone:
+53-42271745
Email address:
yoandraar@infomed.sld.cu
Clinical sites to participate
Section to complete the data related to the clinical sites involved in the trial: site and responsible investigator for every site.
Countries of recruitment:
Cuba
Clinical sites:
Not applicable
Recruitment status
Section to complete information about the recruitment status and the date of first enrolment subject
Recruitment status:
Pending
Date of first enrollment:
01/10/2020
Health condition and Intervention
Section to complete information about the primary medical condition(s) or problem(s) studied and, a characteristics of the intervention(s).
Health condition(s) or Problem(s) studied:
Septic shock
Health condition(s) code:
Shock, Septic
Sepsis
Shock
Pathologic Processes
Systemic Inflammatory Response Syndrome
Pediatrics
Intervention(s):
Group 1 (Experimental): Conventional treatment +Biomodulina T. The conventional treatment(treatment established in the “José Luis Miranda” Pediatic Intensive Care Unit (PICU) based on international consensus and guidelines applied to patients in septic shock) plus Biomodulina T ˂ 1 year ½ bb = 1.5 mg; ≥ 1 year 1 bb = 3 mg, on alternate days the first 14 days, and twice a week the following 14 days, for a total of 11 doses, parenteral route. During admission to the PICU, intravenous route (IV) will be used and, once the patient is discharged from the PICU, it will be used intramuscular route (IM). Group 2 (control): Conventional treatment.
Intervention code:
Immunologic Factors Injections
Injections, Intramuscular
Infusions, Parenteral
Administration, Intravenous
Intervention keyword:
Biomodulin T
Outcomes and Timepoint
Section to complete information about primary and secondary outcomes including. It includes the metric or method of measurement used and, the time point for every outcome.
Primary outcome(s):
1. 28-day mortality (Depending on the condition of the patient, alive or deceased). Measurement time: final evaluation (2 months).
Key secondary outcomes:
1. Organic dysfunction (Number of organs affected (1, 2, 3, more than 3)). Measurement time: in the initial evaluation (day 1). 2. New dysfunction or progression of the previous one (Occurrence (yes or no), Degree of dysfunction (From 0 to 33 points)). Measurement time: in daily evaluations during admission to the PICU. 3. Degree of dysfunction (It will measure through the PELOD questionnaire). Measurement time: in the evaluations during admission to the PICU (Days 1, 2, 5, 8, 12, 16 and 18). If the patient leaves the PICU before any of those days, it is not evaluated. 4. New acquired infection (Occurrence (yes or no), classification (nosocomial or community)). Measurement time: daily evaluations during admission to the PICU, evaluations during treatment with BMT outside the PICU, evaluation at hospital discharge, Final evaluation (2 months). 5. Occurrence of complications (yes or no), Measurement time: daily evaluations during admission to the PICU, Evaluations during treatment with BMT outside the PICU, Evaluation at hospital discharge, Final Evaluation (2 months). 6. PICU stay (days), Measurement time: final evaluation (2 months). 7. Hospital stay (days).Measurement time: final evaluation (2 months). 8 Re-entry within 28 days (Occurrence (yes or no), cause (infectious or non-infectious)). Measurement time: final evaluation (2 months). 9. Nutritional status (Body Mass Index). Measurement time: initial evaluation, evaluation at hospital discharge and final evaluation (2 months). 10. Thymic Area (size in mm2). Measurement time: initial and, final evaluation (2 months). 11. CD4 + count (expressed in cel / µL and in%.). Measurement time: initial and, final evaluation (2 months). 12. Quantification of Immunoglobulins (IgA, IgM, IgG). Measurement time: initial and, final evaluation (2 months). 13. Vital signs (Blood pressure, heart rate, respiratory rate, temperature, oxygen saturation). Measurement time: in evaluations during treatment with BMT, before each administration and 1 h after them. 14. Adverse events (Occurrence (yes or no), Type (describe), Location (local or systemic), Time of appearance (minutes or hours), Duration (hours, minutes or days), Previous knowledge (expected or unexpected), Intensity (mild, moderate or severe), Consequence (severe or not serious), Causal relationship (Very probable / certain, Probable, Possible, Unlikely, Not related, Not evaluable / not classifiable)). Measurement time: in evaluations during BMT treatment, and, in the final evaluation (2 months).
Selection criterias
Section to complete information about the inclusion and exclusion criteria for participant selection, including age and gender.
Gender:
Male/Female
Minimum age:
29 days
Maximum age:
8 years
Inclusion criteria:
1. Patients who meet the diagnostic criteria. 2. Patients aged ≥ 29 days and <9 years. 3. Patients whose parents or legal guardians give their consent to participate in the study in writing.
Exclusion criteria:
1. Patients in whom randomization is not possible within the first 24 hours of being diagnosed. 2. Patients with histories of severe allergic reactions and / or generalized severe eczema. 3. Patients with a diagnosis of tumor or autoimmune disease. 4. Patients with a previous diagnosis of primary immunodeficiency. 5. Patients with a solid organ or stem cell transplant.
Type of population:
Children
Type of participant:
Patients
Study design
Section to complete information about the characteristics of the study design.
Type study:
Interventional
Purpose:
Treatment
Allocation:
Randomized controlled trial
Masking:
Open
Control group:
Active
Study design:
Parallel
Phase:
N/A
Target sample size:
60
Contact for public queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to general queries, including information about current recruitment status
First Name:
Yoandra
Last Name:
Acevedo Rodriguez
Specialty:
First degree specialist Integral General Medicine and First degree in Intensive Therapy and Emergency (pediatric profile).
Affiliation:
"Jose Luis Miranda" Pediatric Hospital.
Postal Address:
July 26th Avenue and 1st. Cast Escambray, Santa Clara
City:
Villa Clara
País:
Cuba
Zip Code:
50200
Telephone:
+53-42271745
Email :
yoandraar@infomed.sld.cu
Contact for scientific queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to scientific queries.
First Name:
Mary
Middle Name:
Carmen
Last Name:
Reyes Zamora
Specialty:
Frist Degree Specialist in Immunology, Master in Clinical Trials
Affiliation:
Centro Nacional de Biopreparados (BioCen), Group of Clinical Trials.
Postal Address:
Carretera Beltran Km 1 ½
City:
Bejucal, Mayabeque
País:
Cuba
Zip Code:
13050, Box 6048
Telephone:
+53-4706682201 -07, ext: 1145 and 1147
Email :
mcarmen.reyes@biocen.cu
Data Sharing
Section to complete the data related to the data sharing plan.
Data sharing plan:
No
Research Ethics Committees
Section to complete the data related to the review ethics committees.
Name of Research Ethics Committees:
"Jose Luis Miranda" Pediatric Hospital
Status of evaluation:
Approved
Status of evaluation date of Ethic Committee:
15/06/2020
Postal address of Ethic Committee :
July 26th Av. and 1st. Cast Escambray, Santa Clara. Villa Clara, Cuba. ZC: 50200
Telephone:
+53-42271745
Correo electrónico:
miranda@capiro.vcl.sld.cu
About study completion
Section to complete the data related to the study completion.
Study completion date:
01/12/2022
Date of available results:
01/05/2023
Date of first publication:
01/11/2023
Registration and Update
Section to complete information about the name of Primary Registry, date of registration and the unique ID number assigned by the registry (RPCEC).
Primary registry:
RPCEC
Unique ID number:
RPCEC00000327
Date of Registration in Primary Registry:
03/08/2020
Record Verification Date:
2020/10/05
Next update date:
2021/10/05
Link to the spanish version:
Click here
Acerca del RPCEC
Estructura y Gobernanza
Política
Publicaciones
Reconocimientos
Comunicaciones
Noticias
Recursos útiles
Fundamentos del registro
Bibliografías en ensayos clínicos
Regulaciones cubanas
Otros registros
Plataforma Internacional de Registros de Ensayos Clínicos